Cancer News and Research

Latest Cancer News and Research

Hormone therapy for treating prostate cancer is linked to heart problems

Berlin, Germany: New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others.

22 Sep 2009

Employees of Vertex Pharmaceuticals take part in volunteer activities

Vertex Pharmaceuticals Incorporated today announced that approximately 800 employees took part in Vertex’s first companywide Day of Service, which was held on Friday, September 18, 2009.

22 Sep 2009

Beech Sandal Company supports breast cancer awareness program

Beech Sandal Company declares its commitment to raising awareness and funding for education, research and treatment for women's health issues by donating its popular, health-oriented Yoga Sandals(R) footwear and a portion of the company's sales to support a number of worthy causes.

22 Sep 2009

Breast Cancer Action launches "Milking Cancer" campaign against Eli Lilly

Breast Cancer Action (BCA), known as the watchdog of the breast cancer movement, today announced the launch of their "Milking Cancer" campaign challenging the pharmaceutical giant Eli Lilly to stop manufacturing rBGH. rBGH (recombinant bovine growth hormone, also known as rBST) has long been linked to cancer.

22 Sep 2009

China SFDA awards Jiangsu Yanshen a new drug certificate and production license for its H1N1 vaccine

Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd ("Jiangsu Yanshen"), in which Simcere holds a 37.5% stake, was awarded a new drug certificate and production license from China's State Food and Drug Administration (SFDA) on September 18 for Jiangsu Yanshen's H1N1 vaccine.

22 Sep 2009

Drug registration process for Nutra Pharma's pain reliever begins

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

22 Sep 2009

WDS conducts free skin cancer screenings

In the most concentrated effort to promote sun safety and skin cancer prevention in the 35-year history of the Women's Dermatologic Society (WDS), volunteer dermatologists in three states recently provided free skin cancer screenings and sun safety education to spectators, professional athletes and media members at four major golf and tennis events throughout the month of August.

22 Sep 2009

"Help is Here Express" bus tour in South Carolina to provide prescription medicines for free

The "Help is Here Express" bus tour will be stopping in South Carolina throughout the week of September 21 - 25 at various cities in order to help uninsured and financially struggling South Carolinians access information on programs that provide prescription medicines for free or nearly free. With the state's unemployment rate now hitting 11.8 percent, the Partnership for Prescription Assistance (PPA) bus tour is raising awareness of patient assistance programs among state residents who face layoffs and loss of health care benefits.

22 Sep 2009

Data show a decrease in ozone layer

By merging more than a decade of atmospheric data from European satellites, scientists have compiled a homogeneous long-term ozone record that allows them to monitor total ozone trends on a global scale - and the findings look promising.

22 Sep 2009

Major shift in cancer research priorities needed

Cancer research is too focused on new drug development, while not enough money and effort is being devoted to pursuing important advances in knowledge likely to have the biggest impact on combating the disease in the next few decades, a leading research policy expert says, adding that a major shift in research priorities will be crucial to the ability to cope with the coming wave of cancer cases.

22 Sep 2009

Health Robotics chooses Device Technologies Australia as its exclusive CytoCare partner for Oceania

Health Robotics today announced that it has signed an exclusive five-year strategic partnership with Device Technologies Australia Pty Ltd. for its revolutionary CytoCare(TM) Robot. This strategic agreement enables Device Technologies Australia to achieve its goal of safely, accurately and cost-effectively automating the preparation of Oncology I.V. Admixtures to complement its other market-leading Oncology and Surgery Robotic solutions.

22 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Moses Cone Health System installs TomoTherapy cancer treatment system

TomoTherapy Incorporated announced today that Moses Cone Health System has installed North Carolina's first TomoTherapy® cancer treatment system at the Moses Cone Regional Cancer Center in Greensboro, N.C.

22 Sep 2009

Barbershop singing helps cancer-survivor

For Marguerite Paustenbach, her secret weapon in the fight against breast cancer turned out to be her strong faith and love for barbershop singing. Paustenbach is a member of Village Vocal Chords, a Chicago-based barbershop singing group that’s part of Harmony, Inc., an all women’s barbershop singing organization currently celebrating its 50th anniversary.

22 Sep 2009

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009

Rexahn and Teva sign license and stock purchase agreements

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.

22 Sep 2009

Research to study how eukaryotic cells help in building proteins

Federal stimulus funding is helping a Kansas State University biologist continue to collaborate with the Harvard Medical School. Their research is creating a clearer picture of a certain cellular process that can play a role in chronic diseases like cancer.

22 Sep 2009

MRS could be effective for identifying diabetes

Researchers have long suspected that overweight people tend to have large fat deposits in their pancreases, but they've been unable to confirm or calculate how much fat resides there because of the organ's location.

22 Sep 2009

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

UC professor argues on stem cell properties

Before it was learned that matter burns by taking up oxygen, most chemists sought to explain combustion as the release of a mysterious substance, which they named "phlogiston". Phlogiston theory was a conceptual breakthrough that helped chemists conduct experiments and share ideas. Only when it came to pinning down the distinctive physical properties of phlogiston did it become clear that no such thing exists.

22 Sep 2009